Rigel Pharmaceuticals(RIGL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RIGL Rigel Pharmaceuticals

交易中 09-01 14:24:40 EDT

47.35

+1.17

+2.53%

最高47.44	最低46.15	成交量9.60万
今开46.15	昨收46.18	日振幅2.79%
总市值8.84亿	流通市值7.03亿	总股本1,868万
成交额451.20万	换手率0.65%	流通股本1,485万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RIGL","market":"US","secType":"STK","nameCN":"Rigel Pharmaceuticals","latestPrice":47.35,"timestamp":1788287075959,"preClose":46.18,"halted":0,"volume":96023,"delay":0,"changeRate":0.025335643135556554,"floatShares":14846600,"shares":18679864,"eps":16.450558,"marketStatus":"交易中","change":1.17,"latestTime":"09-01 14:24:40 EDT","open":46.15,"high":47.44,"low":46.15,"amount":4512021.86631,"amplitude":0.027934,"askPrice":47.39,"askSize":109,"bidPrice":47.31,"bidSize":508,"shortable":3,"etf":0,"ttmEps":16.450558,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1788292800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":975474000000,"exchange":"NASDAQ","adjPreClose":46.18,"preHourTrading":{"tag":"盘前","latestPrice":46.18,"preClose":46.18,"latestTime":"08:18 EDT","volume":6,"amount":277.08,"timestamp":1788265129593,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":46,"preClose":46.18,"latestTime":"19:44 EDT","volume":28131,"amount":1299071.58,"timestamp":1788219894246,"change":-0.18,"changeRate":-0.003898,"amplitude":0.003898},"volumeRatio":0.486209,"impliedVol":0.4202,"impliedVolPercentile":0.0873},"requestUrl":"/m/hq/s/RIGL","defaultTab":"news","newsList":[{"id":"1147653562","title":"Rigel宣布Veppanu™（Vepdegestrant）正式上市，用于ER+/HER2-、ESR1突变型晚期或转移性乳腺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1147653562","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147653562?lang=zh_cn&edition=full","pubTime":"2026-08-13 20:07","pubTimestamp":1786622856,"startTime":"0","endTime":"0","summary":"Rigel Pharmaceuticals正式宣布，其自主研发的Veppanu™（Vepdegestrant）现已全面上市。这款靶向治疗药物，专门针对ER阳性、HER2阴性且携带ESR1基因突变的晚期或转移性乳腺癌患者。该消息一经发布，便迅速在肿瘤治疗领域引发广泛关注。对于此前内分泌治疗无果或进展的患者而言，这一新药或将带来全新的治疗选择。Rigel通过精准的研发路径，将药物迅速推向临床，意在填补当前治疗领域中的关键空白。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RIGL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136500156","title":"Rigel Pharmaceuticals任命Alison L. Hannah为执行副总裁兼首席医疗官，2026年7月1日生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1136500156","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136500156?lang=zh_cn&edition=full","pubTime":"2026-07-02 04:14","pubTimestamp":1782936870,"startTime":"0","endTime":"0","summary":"Rigel Pharmaceuticals宣布了一项重要的人事任命。Alison L. Hannah女士将于2026年7月1日正式加入公司，担任执行副总裁兼首席医疗官。作为新任首席医疗官，Hannah女士将负责领导公司的全球临床开发、药政事务及医疗事务团队。这一任命旨在加强Rigel在关键治疗领域的临床开发战略和执行能力。Rigel Pharmaceuticals致力于发现、开发并为患者提供新型小分子药物，其研发重点集中于血液学、肿瘤学及免疫学相关疾病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RIGL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157887878","title":"Arvinas与辉瑞携手Rigel Pharmaceuticals，就Veppanu（Vepdegestrant）达成全球独家授权交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1157887878","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157887878?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:01","pubTimestamp":1778583714,"startTime":"0","endTime":"0","summary":"Arvinas Holding Company LLC与辉瑞公司已同Rigel Pharmaceuticals达成一项协议，获得其药物Veppanu（Vepdegestrant）的全球独家权利。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000M9KFDE8.USD","BK4585","IE0002270589.USD","SG9999001176.USD","IE00B3T34201.USD","SGXZ57979304.SGD","LU0058720904.USD","SG9999002224.SGD","LU0234572021.USD","LU1894683348.USD","LU0170899867.USD","LU0306806265.USD","IE00B19Z3581.USD","BK4592","LU1066051498.USD","IE00BBT3K403.USD","SG9999002232.USD","PFE","SG9999013999.USD","LU0321505868.SGD","LU1894683264.USD","RIGL","BK4534","IE00BLSP4452.SGD","LU0122379950.USD","ARVN","BK4533","BK4588","IE00B19Z3B42.SGD","SG9999003800.SGD","LU0225771236.USD","LU0868494617.USD","LU0456855351.SGD","BK4581","LU0225284248.USD","LU0289739699.SGD","LU0306807586.USD","SG9999001176.SGD","LU1057294990.SGD","LU1883839398.USD","SG9999011175.SGD","LU0985481810.HKD","BK4007","BK4550","BK4568","IE00BLSP4239.USD","BK4599","LU1066053197.SGD","LU1023059063.AUD","LU0321505439.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139312148","title":"Rigel Pharmaceuticals 就口服PROTAC药物Veppanu™达成独家全球许可协议，用于治疗2L+ ER+/HER2-、ESR1突变晚期或转移性乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1139312148","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139312148?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:01","pubTimestamp":1778583687,"startTime":"0","endTime":"0","summary":"Rigel Pharmaceuticals 已就口服PROTAC药物Veppanu™（通用名：Vepdegestrant）达成了一项独家全球许可协议。该药物旨在用于治疗二线及以后（2L+）的雌激素受体阳性/人表皮生长因子受体2阴性（ER+/HER2-）、且携带雌激素受体1（ESR1）突变的晚期或转移性乳腺癌患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RIGL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167115232","title":"Kissei制药将获台湾商业化预付款及里程碑款项 并向Oep供应制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1167115232","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167115232?lang=zh_cn&edition=full","pubTime":"2026-05-01 14:35","pubTimestamp":1777617312,"startTime":"0","endTime":"0","summary":"Kissei制药株式会社宣布，公司将基于产品在台湾地区的商业化进展获得预付款及里程碑付款，同时将向Oep供应制剂产品。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RIGL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144599187","title":"Kissei制药与台湾东洋欧化达成\"Olutasidenib\"许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1144599187","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144599187?lang=zh_cn&edition=full","pubTime":"2026-05-01 14:34","pubTimestamp":1777617255,"startTime":"0","endTime":"0","summary":"日本Kissei制药株式会社宣布，已与台湾东洋欧化制药就白血病治疗药物\"Olutasidenib\"达成独家许可协议。根据协议条款，东洋欧化制药将获得该药物在台湾地区的独家开发和商业化权利。\n此次合作标志着Kissei制药在拓展亚洲市场战略布局的重要一步。Olutasidenib作为一种创新靶向药物，在急性髓系白血病治疗领域展现出显著临床潜力。通过本次授权合作，将加速该创新疗法在台湾地区的可及性，为当地患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195200222","title":"Rigel制药公司：协议终止后不再预期未来里程碑或特许权使用费——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1195200222","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195200222?lang=zh_cn&edition=full","pubTime":"2026-04-22 04:22","pubTimestamp":1776802958,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的最新文件，Rigel制药公司（Rigel Pharmaceuticals）确认，在相关协议终止后，公司将不再预期获得任何未来的里程碑付款或特许权使用费收入。\n这一披露意味着该公司原先基于该协议规划的潜在现金流已被正式移除。协议的终止对Rigel的财务前景产生了直接影响，消除了此前预期中的一部分收入来源。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2471134796.USD","LU0320765992.SGD","LU2417539215.USD","LU0820561909.HKD","LU0823434583.USD","LU0114720955.EUR","LU2462157665.USD","LU2491050071.SGD","IE0001KFT4U8.USD","LU1712237335.SGD","LU2324357040.USD","LU1720051108.HKD","LU2265009873.SGD","LU1035775433.USD","LU0256863902.USD","LU2106854487.HKD","LU2756315318.SGD","LU2023251221.USD","LU2168564495.EUR","SGXZ81514606.USD","SG9999001176.SGD","LU0432979614.USD","LU1093756325.SGD","LU2089284900.SGD","LU2360106947.USD","LU1127390331.HKD","LU1023059063.AUD","LU1814569148.SGD","LU2491049909.HKD","LU2468319806.SGD","LU2361044949.HKD","LU0158827781.USD","IE00BKDWB100.SGD","IE00B1XK9C88.USD","LU0820562030.AUD","LU2089283258.USD","LU2089984988.USD","LU0097036916.USD","LU2471134523.USD","LU1917777945.USD","LU0106261372.USD","IE00B4R5TH58.HKD","LU1868836914.USD","LU2357305700.SGD","IE00B4JS1V06.HKD","LU1551013425.SGD","LLII","SG9999015986.USD","LU0109391861.USD","IE00B7KXQ091.USD","LU2108987350.USD","LU0353189763.USD","LU2602419157.SGD","GB00BDT5M118.USD","LU0316494557.USD","LU1232071149.USD","LU0094547139.USD","LU0471298694.HKD","LU0466842654.USD","LU0889565916.HKD","LU2237443978.SGD","BK4585","LU0203202063.USD","LU0787776722.HKD","LU1989771016.USD","LU2237443895.HKD","LU1064131342.USD","LU0225283273.USD","IE00B775H168.HKD","LU0882574139.USD","LU1069344957.HKD","LU2361045086.USD","LU2456880835.USD","SGXZ31699556.SGD","IE00BWXC8680.SGD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU2552382215.SGD","LU2746668974.SGD","RIGL","LU2746668461.USD","LU2063271972.USD","LU0256863811.USD","LU0385154629.USD","IE0002141913.USD","LU2552382132.HKD","LU2237443465.HKD","LU1093756168.USD","LU2264538146.SGD","LU1868836591.USD","LU2491050154.USD","IE00BFTCPJ56.SGD","IE0004445015.USD","LU1974910355.USD","BK4581","LU2023250330.USD","ELIS","IE00BK4W5L77.USD","LU0289739699.SGD","LU2237443549.SGD","LU2471134879.HKD","BK4599","LU1868837300.USD","IE00BKPKM429.USD","LU0061475181.USD","SG9999014914.USD","LU2028103732.USD","IE00B1BXHZ80.USD","LU0456855351.SGD","LU0234572021.USD","IE00BJLML261.HKD","LU0203201768.USD","IE0009355771.USD","LU0882574055.USD","LU1267930730.SGD","LU0158827948.USD","BK4534","LU0323591593.USD","LU0471298777.SGD","LU0943347566.SGD","LU0823416689.USD","LU1323610961.USD","SG9999013999.USD","LU0006306889.USD","LU2750360997.AUD","LU0198837287.USD","SGXZ51526630.SGD","LU0320765059.SGD","LU1629891620.HKD","ELIL","IE00BK4W5M84.HKD","LU2112291526.USD","LU0109394709.USD","BK4007","LU0079474960.USD","SG9999015952.SGD","SG9999018857.SGD","LU1868836757.USD","LU1983299246.USD","LLYZ","IE00B2B36J28.USD","LU2236285917.USD","LU2168564222.USD","LU0672654240.SGD","LU2237443382.USD","LU2271345857.HKD","LU2750360641.GBP","IE0004445239.USD","LU2552382058.USD","LU0683600562.USD","LU0823434740.USD","LU2237438978.USD","LU2168564149.EUR","LU0122379950.USD","LU1548497426.USD","SG9999015945.SGD","LU1988902786.USD","LU2087625088.SGD","LU0353189680.USD","LLYX","LU2168564065.EUR","LU2168563687.JPY","LU0210536198.USD","LU0058720904.USD","LU0640476718.USD","LU2361044865.SGD","IE00BJJMRX11.SGD","LU1280957306.USD","LU1804176565.USD","LU2023250504.SGD","LU1366192091.USD","SG9999018865.SGD","SGXZ57979304.SGD","BK4139","BK4516","LU0133085943.USD","LU2213496289.HKD","SG9999015978.USD","BK4588","SG9999014898.SGD","LU0266013472.USD","LU0238689110.USD","LU2237443622.USD","SG9999017495.SGD","LU2211815571.USD","LU0354030511.USD","SGXZ99366536.SGD","LU0354030438.USD","LU1057294990.SGD","IE0005OL40V9.USD","LU0708995401.HKD","LU0786609619.USD","BK4533","LU2461242641.AUD","LU1061106388.HKD","LU0417517546.SGD","LU1291159041.SGD","LU0096364046.USD","LU1720051017.SGD","LU2111349929.HKD","SG9999014880.SGD","LU2471134952.CNY","IE00BFSS7M15.SGD","SG9999001176.USD","SG9999014906.USD","LU0689472784.USD","LU1623119135.USD","LU2756315664.SGD","LU0964807845.USD","LU1551013342.USD","IE00BJJMRY28.SGD","LU1145028129.USD","LU0820561818.USD","LU1868837136.USD","IE00BN29S564.USD","IE00BFSS8Q28.SGD","LU2896262040.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103233203","title":"Rigel公布Gavreto®（普拉塞替尼）治疗RET+非小细胞肺癌ARROW临床试验最终数据于《临床肿瘤学杂志》发表","url":"https://stock-news.laohu8.com/highlight/detail?id=1103233203","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103233203?lang=zh_cn&edition=full","pubTime":"2026-03-31 20:06","pubTimestamp":1774958779,"startTime":"0","endTime":"0","summary":"Rigel Pharmaceuticals宣布，其Gavreto®（普拉塞替尼）用于治疗RET融合阳性非小细胞肺癌（RET+ NSCLC）患者的ARROW临床试验最终数据，已在权威期刊《临床肿瘤学杂志》（Journal of Clinical Oncology）上正式发表。该数据的公布标志着这一靶向疗法在临床研究领域的重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518614275","title":"Rigel Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.75%报19.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518614275","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518614275?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:54","pubTimestamp":1741614856,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时54分，Rigel Pharmaceuticals, Inc.股票出现波动，股价急速下挫5.75%。Rigel Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为2864.76%、638.63%、141.33%，振幅较大的相关个股有Scisparc Ltd.、Impact Biomedical, Inc.、Trevi Therapeutics, Inc.，振幅分别为40.24%、28.59%、25.35%。Rigel Pharmaceuticals, Inc.公司简介：里格尔制药有限公司开发用于自身免疫性疾病、癌症相关疾病和病毒性疾病的小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021541798a2a2f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021541798a2a2f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RIGL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517421161","title":"花旗：维持Rigel Pharmaceuticals(RIGL.US)评级，由买入调整至买入评级, 目标价由49.00美元调整至55.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517421161","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517421161?lang=zh_cn&edition=full","pubTime":"2025-03-06 23:22","pubTimestamp":1741274556,"startTime":"0","endTime":"0","summary":"花旗：维持Rigel Pharmaceuticals(RIGL.US)评级，由买入调整至买入评级, 目标价由49.00美元调整至55.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06232248576365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517948320","title":"Rigel Pharmaceuticals, Inc.盘中异动 早盘快速下挫8.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517948320","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517948320?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:31","pubTimestamp":1741185079,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时31分，Rigel Pharmaceuticals, Inc.股票出现波动，股价快速下挫8.49%。Rigel Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Zyversa Therapeutics, Inc.较为活跃，换手率分别为318.54%、251.99%、184.79%，振幅较大的相关个股有Aditxt, Inc.、天境生物、Dianthus Therapeutics, Inc.，振幅分别为23.90%、11.10%、9.87%。Rigel Pharmaceuticals, Inc.公司简介：里格尔制药有限公司开发用于自身免疫性疾病、癌症相关疾病和病毒性疾病的小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223119a260c717&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223119a260c717&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517983989","title":"Rigel Pharmaceuticals(RIGL.US)：2024年Q4财报实现营收5759.6万美元，前值为3579.2万美元，预期值为5759万美元；每股收益为0.80美元，前值为0.04美元，预期值为0.55美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517983989","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517983989?lang=zh_cn&edition=full","pubTime":"2025-03-05 05:11","pubTimestamp":1741122692,"startTime":"0","endTime":"0","summary":"Rigel Pharmaceuticals(RIGL.US)：2024年Q4财报实现营收5759.6万美元，前值为3579.2万美元，预期值为5759万美元；每股收益为0.80美元，前值为0.04美元，预期值为0.55美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/05051148524473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155217362","title":"Rigel Pharmaceuticals第四季度每股收益$0.80，超出预期$0.47，销售额$57.60M，超出预期$51.73M","url":"https://stock-news.laohu8.com/highlight/detail?id=1155217362","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155217362?lang=zh_cn&edition=full","pubTime":"2025-03-05 05:10","pubTimestamp":1741122639,"startTime":"0","endTime":"0","summary":"Rigel Pharmaceuticals 报告季度每股收益为$0.80，高出分析师预期的$0.47，超出幅度为70.21%。这是较去年同期每股收益$0.04增长了1900%。以上内容来自Benzinga Earnings专栏，原文如下：$Rigel Pharmaceuticals$  reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.47 by 70.21 percent. This is a 1900 percent increase over earnings of $0.04 per share from the same period last year.  The company reported quarterly sales of $57.60 million which beat the analyst consensus estimate of $51.73 million by 11.34 percent.  This is ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Rigel Pharmaceuticals第四季度每股收益$0.80，超出预期$0.47，销售额$57.60M，超出预期$51.73M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514085743","title":"Rigel Pharmaceuticals, Inc.盘中异动 大幅上涨5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514085743","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514085743?lang=zh_cn&edition=full","pubTime":"2025-02-27 00:08","pubTimestamp":1740586113,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日00时08分，Rigel Pharmaceuticals, Inc.股票出现波动，股价快速拉升5.19%。Rigel Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.25%。其相关个股中，Enveric Biosciences, Inc.、Pds Biotechnology Corporation、Pasithea Therapeutics Corp C/Wts 12/08/2026 涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为5651.73%、210.39%、202.73%，振幅较大的相关个股有Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 ，振幅分别为161.02%、43.31%、41.71%。Rigel Pharmaceuticals, Inc.公司简介：里格尔制药有限公司开发用于自身免疫性疾病、癌症相关疾病和病毒性疾病的小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227000833a2550da8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227000833a2550da8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513727364","title":"Rigel Pharmaceuticals, Inc.盘中异动 大幅上涨5.53%报21.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513727364","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513727364?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:38","pubTimestamp":1740407923,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时38分，Rigel Pharmaceuticals, Inc.股票出现波动，股价急速拉升5.53%。Rigel Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Pepgen Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为55.26%、47.30%、24.53%，振幅较大的相关个股有Pepgen Inc.、Vaxart, Inc. - Common Stock、Gossamer Bio, Inc.，振幅分别为92.70%、21.42%、14.69%。Rigel Pharmaceuticals, Inc.公司简介：里格尔制药有限公司开发用于自身免疫性疾病、癌症相关疾病和病毒性疾病的小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242238449890f78c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242238449890f78c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510332937","title":"Rigel Pharmaceuticals, Inc.盘中异动 临近午盘大幅下挫5.13%报20.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510332937","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510332937?lang=zh_cn&edition=full","pubTime":"2025-02-12 01:00","pubTimestamp":1739293214,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日01时00分，Rigel Pharmaceuticals, Inc.股票出现异动，股价急速跳水5.13%。Rigel Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.55%。其相关个股中，Omega Therapeutics, Inc.、Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为3007.57%、1338.48%、438.53%，振幅较大的相关个股有Omega Therapeutics, Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.，振幅分别为143.33%、59.46%、58.60%。Rigel Pharmaceuticals, Inc.公司简介：里格尔制药有限公司开发用于自身免疫性疾病、癌症相关疾病和病毒性疾病的小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212010014961f612e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212010014961f612e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510653928","title":"Rigel Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.26%报20.79美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510653928","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510653928?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:44","pubTimestamp":1739198644,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时44分，Rigel Pharmaceuticals, Inc.股票出现波动，股价急速下挫5.26%。Rigel Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。其相关个股中，Biodexa Pharmaceuticals Plc、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Neurosense Therapeutics Ltd C/Wts 10/11/2026 涨幅较大，Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.较为活跃，换手率分别为2016.42%、1139.65%、727.94%，振幅较大的相关个股有Biodexa Pharmaceuticals Plc、Ocean Biomedical, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为53.32%、39.80%、39.13%。Rigel Pharmaceuticals, Inc.公司简介：里格尔制药有限公司开发用于自身免疫性疾病、癌症相关疾病和病毒性疾病的小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021022440498807ad0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021022440498807ad0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RIGL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509201406","title":"Rigel Pharmaceuticals, Inc.盘中异动 股价大涨5.04%报23.99美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509201406","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509201406?lang=zh_cn&edition=full","pubTime":"2025-02-07 00:53","pubTimestamp":1738860783,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日00时53分，Rigel Pharmaceuticals, Inc.股票出现异动，股价大幅拉升5.04%。Rigel Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.01%。其相关个股中，Lipella Pharmaceuticals Inc.、Geovax Labs Inc C/Wts 29/09/2025、Palatin Technologies, Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Azitra Inc较为活跃，换手率分别为5904.30%、1567.01%、158.59%，振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Palatin Technologies, Inc.，振幅分别为125.58%、53.02%、49.54%。Rigel Pharmaceuticals, Inc.公司简介：里格尔制药有限公司开发用于自身免疫性疾病、癌症相关疾病和病毒性疾病的小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207005303987ca487&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207005303987ca487&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509235876","title":"Rigel Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.11%报21.93美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509235876","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509235876?lang=zh_cn&edition=full","pubTime":"2025-02-06 00:01","pubTimestamp":1738771303,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日00时01分，Rigel Pharmaceuticals, Inc.股票出现波动，股价急速上涨5.11%。Rigel Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.29%。其相关个股中，Transcode Therapeutics, Inc.、Oragenics Inc.、Pasithea Therapeutics Corp.涨幅较大，Pasithea Therapeutics Corp.、Transcode Therapeutics, Inc.、Oragenics Inc.较为活跃，换手率分别为4203.78%、1492.21%、1274.54%，振幅较大的相关个股有Transcode Therapeutics, Inc.、Oragenics Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028，振幅分别为96.10%、59.80%、54.05%。Rigel Pharmaceuticals, Inc.公司简介：里格尔制药有限公司开发用于自身免疫性疾病、癌症相关疾病和病毒性疾病的小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206000143987b8c4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206000143987b8c4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RIGL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508149798","title":"Rigel Pharmaceuticals, Inc.盘中异动 股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508149798","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508149798?lang=zh_cn&edition=full","pubTime":"2025-02-03 22:31","pubTimestamp":1738593115,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日22时31分，Rigel Pharmaceuticals, Inc.股票出现异动，股价快速下挫5.08%。Rigel Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.29%。其相关个股中，Hcw Biologics Inc.、Gh Research Plc、Briacell Therapeutics Corp.涨幅较大，Hcw Biologics Inc.、Briacell Therapeutics Corp.、Cyclerion Therapeutics, Inc.较为活跃，换手率分别为313.51%、209.90%、126.36%，振幅较大的相关个股有Hcw Biologics Inc.、Briacell Therapeutics Corp.、Tc Biopharm  Plc，振幅分别为14.02%、11.95%、11.75%。Rigel Pharmaceuticals, Inc.公司简介：里格尔制药有限公司开发用于自身免疫性疾病、癌症相关疾病和病毒性疾病的小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203223155a2380944&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203223155a2380944&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RIGL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rigel.com","stockEarnings":[{"period":"1week","weight":0.0237},{"period":"1month","weight":0.2546},{"period":"3month","weight":0.5383},{"period":"6month","weight":0.5586},{"period":"1year","weight":0.1887},{"period":"ytd","weight":0.0782}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.0268},{"period":"3month","weight":0.0098},{"period":"6month","weight":0.1196},{"period":"1year","weight":0.1891},{"period":"ytd","weight":0.1248}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Rigel Pharmaceuticals, Inc.于1996年6月14日成立于特拉华州。该公司是一家生物技术公司，致力于发现、开发和提供新疗法，显著改善血液系统疾病和癌症患者的生活。公司首个获FDA批准的产品是TAVALISSE（六水二钠福司他马替尼）片，这是唯一获批的口服脾脏酪氨酸激酶（SYK）抑制剂，用于治疗对先前治疗反应不足的慢性免疫性血小板减少症（ITP）成人患者。该公司第二个获得FDA批准的产品是REZLIDHIA（olutasidenib）胶囊，用于治疗经FDA批准的试验检测出具有易感异柠檬酸脱氢酶-1（IDH1）突变的复发或难治性（R/R）急性髓系白血病（AML）成人患者。","yearOnYearQuotes":[{"month":1,"riseRate":0.384615,"avgChangeRate":-0.021118},{"month":2,"riseRate":0.423077,"avgChangeRate":-0.030269},{"month":3,"riseRate":0.5,"avgChangeRate":0.003676},{"month":4,"riseRate":0.538462,"avgChangeRate":0.029561},{"month":5,"riseRate":0.346154,"avgChangeRate":0.000389},{"month":6,"riseRate":0.423077,"avgChangeRate":0.018481},{"month":7,"riseRate":0.5,"avgChangeRate":-0.001375},{"month":8,"riseRate":0.461538,"avgChangeRate":0.045473},{"month":9,"riseRate":0.48,"avgChangeRate":0.019365},{"month":10,"riseRate":0.4,"avgChangeRate":-0.057423},{"month":11,"riseRate":0.44,"avgChangeRate":0.081471},{"month":12,"riseRate":0.461538,"avgChangeRate":0.119534}],"exchange":"NASDAQ","name":"Rigel Pharmaceuticals","nameEN":"Rigel Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rigel Pharmaceuticals(RIGL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Rigel Pharmaceuticals(RIGL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Rigel Pharmaceuticals,RIGL,Rigel Pharmaceuticals股票,Rigel Pharmaceuticals股票老虎,Rigel Pharmaceuticals股票老虎国际,Rigel Pharmaceuticals行情,Rigel Pharmaceuticals股票行情,Rigel Pharmaceuticals股价,Rigel Pharmaceuticals股市,Rigel Pharmaceuticals股票价格,Rigel Pharmaceuticals股票交易,Rigel Pharmaceuticals股票购买,Rigel Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rigel Pharmaceuticals(RIGL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Rigel Pharmaceuticals(RIGL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}